Beta Thalassemia Testing Market Research and Forecast by 2032Posted by Ganesh Shinde on March 7th, 2023 ![]() The beta thalassemia testing market is expected to be worth 5.57 million in 2022 and increase at an 8.2% CAGR to reach 3.62 million by 2032. Beta thalassemia can be defined as a blood disorder characterised by decreased haemoglobin production. Hemoglobin is an iron-containing protein found in red blood cells. Its primary purpose is to transport oxygen to body cells throughout the body. A shortage of haemoglobin in beta thalassemia patients frequently results in a loss of oxygen in numerous regions of the body. The complexion of the patient turns pale yellow due to a lack of blood in the body, and other symptoms such as weakness and exhaustion are noticeable. Patients with beta thalassemia are at a significant risk of irregular blood clotting. Regional Insights: North America is expected to account for a large percentage of the global market for beta thalassemia testing. The presence of large market participants in the area, as well as strong healthcare infrastructure, is credited with driving market expansion. The Asia Pacific beta thalassemia testing market is expected to expand rapidly over the forecast period. Increased awareness of the importance of early diagnosis, as well as an increase in the number of beta thalassemia patients, are expected to drive the market. Browse More@ https://www.futuremarketinsights.com/reports/beta-thalassemia-testing-market Beta Thalassemia Testing Market Based on technology, the beta thalassemia testing Market is segmented into the following:
Based on end user, the in vivo imaging systems market can be segmented into following:
Based on geography, the in vivo Imaging Systems market is segmented into following:
Like it? Share it!More by this author |